NCT00724854View on ClinicalTrials.gov

Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)

CompletedOBSERVATIONAL

Enrollment

1,146

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Hepatitis C, ChronicHepatitis C

Interventions

BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

PegIntron administered in accordance with approved labeling

DRUG

Rebetol (ribavirin; SCH 18908)

Rebetol administered in accordance with approved labeling

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724854 - Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) | Biotech Hunter | Biotech Hunter